Polio cases have continued  primarily due of insurrection in the border area between Afghanistan and Pakistan. Nigeria has been polio free in 2019 and we are cautionly optimistic that the entire continent of Africa is on the path to being certified to be polio free. We must keep up the fight and hope that the Taliban can reach an agreement to allow our polio workers to continue their work in the last bastion of the wild polio virus.
Polio this week as of 17 July 2019
 
 
 
Headlines:
  • In Central African Republic, a series of previously-detected/reported VDPV2s have now been officially classified as ‘circulating’.  Since initial detection of the viruses in May, the country had already operationally considered these viruses to represent an outbreak and implemented emergency outbreak response and declared the event to be a national public health emergency.
  • A cVDPV2 originating in Jigawa, Nigeria, continues to spread.  Genetically-linked virus has been confirmed from an environmental sample in Ghana.
  • In Myanmar, a cVDPV1 has been reported and response measures are being implemented.  Neighbouring countries have been informed of the confirmed cVDPV1, and surveillance for polioviruses is being strengthened across the region.  Myanmar had previously successfully stopped a cVDPV2 outbreak in 2015.
  • Summary of new viruses this week: Afghanistan — one wild poliovirus type 1 (WPV1) case and one WPV1-positive environmental sample; Pakistan— four WPV1 cases and three WPV1-positive environmental samples; Nigeria —three circulating vaccine-derived poliovirus type 2 (cVDPV2) cases, two cVDPV2-positive environmental samples, and one cVDPV2 isolated from a healthy contact; Democratic Republic of Congo (DRC) — five cVDPV2 cases; Central African Republic (CAR) — three cVDPV2 cases, one case classified cVDPV2 based on a positive contact, and ten cVDPV2 community/close contacts ; Angola — one cVDPV2 isolated from healthy child; Ghana — one cVDPV2-positive environmental sample linked to Jigawa/Nigeria outbreak; Myanmar — two cVDPV1 cases and two cVDPV1 positive contacts.
  Afghanistan: 
  • One wild poliovirus type 1 (WPV1) case has been reported in the past week in Musaqalah district, Hilmand province. The onset of paralysis was on 5 June 2019. There are 11 WPV1 cases reported in 2019 from Afghanistan. The total number of WPV1 cases for 2018 remains 21.
  • One WPV1-positive environmental sample was reported in the past week from Kandahar district, Kandahar province. The sample was collected on 24 June 2019.
 Pakistan:
  • Four wild poliovirus type 1 (WPV1) cases have been reported in the past week: One each from Jehlum and Lahore districts, Punjab province, with onset of paralysis on 21 and 22 June 2019; one each from Bannu and Lakkimarwat districts, Khyber Pakhtunkhwa province, with onset of paralysis on 22 June and 01 July 2019. The total number of WPV1 cases are 45.
  • Three WPV1-positive environmental samples were reported in the past week: one each from Quetta district in Balochistan province; Karachi district in Sindh province; Bannu district in Khyber Pakhtunkhwa province. The samples were collected between 20-27 June 2019.
  Nigeria:
  • Three cases of circulating vaccine-derived poliovirus type 2 have been reported in the past week: one each from Wurno LGA, Sokoto State, Irewole LGA, Osun State and Baruten LGA, Kwara State. The onset of paralysis was on 20 May, 9 June and 14 June 2019 respectively. There are 12 cVDPV2 cases reported in 2019 so far. The total number of cVDPV2 cases in 2018 remains 34.
  • Two positive environmental samples were reported in the past week: Sokoto North LGA, Sokoto State and Ilorin West LGA, Kwara State. The samples were collected on 10 and 13 June 2019 respectively.
  • One cVDPV2 was isolated from a healthy child from Wurno LGA, Sokoto State. The sample was collected on 20 June 2019.
  • Recent confirmation of spread of one of the cVDPV2 outbreaks, both within Nigeria and internationally, underscores the urgent need to fill remaining vaccination gaps in the ongoing outbreak response, and to optimize the geographic extent and operational quality of mOPV2 response.